156 related articles for article (PubMed ID: 9535168)
1. Arisugacins, selective acetylcholinesterase inhibitors of microbial origin.
Otoguro K; Kuno F; Omura S
Pharmacol Ther; 1997; 76(1-3):45-54. PubMed ID: 9535168
[TBL] [Abstract][Full Text] [Related]
2. Arisugacins A and B, novel and selective acetylcholinesterase inhibitors from Penicillium sp. FO-4259. I. Screening, taxonomy, fermentation, isolation and biological activity.
Kuno F; Otoguro K; Shiomi K; Iwai Y; Omura S
J Antibiot (Tokyo); 1996 Aug; 49(8):742-7. PubMed ID: 8823504
[TBL] [Abstract][Full Text] [Related]
3. Arisugacins C and D, novel acetylcholinesterase inhibitors and their related novel metabolites produced by Penicilium sp. FO-4259-11.
Otoguro K; Shiomi K; Yamaguchi Y; Arai N; Sunazuka T; Masuma R; Iwai Y; Omura S
J Antibiot (Tokyo); 2000 Jan; 53(1):50-7. PubMed ID: 10724008
[TBL] [Abstract][Full Text] [Related]
4. Arisugacin, a novel and selective inhibitor of acetylcholinesterase from Penicillium sp. FO-4259.
Omura S; Kuno F; Otoguro K; Sunazuka T; Shiomi K; Masuma R; Iwai Y
J Antibiot (Tokyo); 1995 Jul; 48(7):745-6. PubMed ID: 7649881
[No Abstract] [Full Text] [Related]
5. Arisugacins A and B, novel and selective acetylcholinesterase inhibitors from Penicillium sp. FO-4259. II. Structure elucidation.
Kuno F; Shiomi K; Otoguro K; Sunazuka T; Omura S
J Antibiot (Tokyo); 1996 Aug; 49(8):748-51. PubMed ID: 8823505
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase Inhibitory Arisugacins L-Q from a
Dai W; Sandoval IT; Cai S; Smith KA; Delacruz RGC; Boyd KA; Mills JJ; Jones DA; Cichewicz RH
J Nat Prod; 2019 Sep; 82(9):2627-2637. PubMed ID: 31433188
[TBL] [Abstract][Full Text] [Related]
7. Efficient total synthesis of novel bioactive microbial metabolites.
Sunazuka T; Hirose T; Omura S
Acc Chem Res; 2008 Feb; 41(2):302-14. PubMed ID: 18217720
[TBL] [Abstract][Full Text] [Related]
8. (+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.
Al-Rashid ZF; Hsung RP
Bioorg Med Chem Lett; 2011 May; 21(9):2687-91. PubMed ID: 21216144
[TBL] [Abstract][Full Text] [Related]
9. Highly functionalized 2-amino-4H-pyrans as potent cholinesterase inhibitors.
Kumar RS; Almansour AI; Arumugam N; Al-Thamili DM; Basiri A; Kotresha D; Manohar TS; Venketesh S; Asad M; Asiri AM
Bioorg Chem; 2018 Dec; 81():134-143. PubMed ID: 30121001
[TBL] [Abstract][Full Text] [Related]
10. Determination of absolute stereochemistries of arisugacin F and Territrem B, novel acetylcholinesterase inhibitors.
Handa M; Sunazuka T; Nagai K; Kimura R; Otoguro K; Harigaya Y; Omura S
J Antibiot (Tokyo); 2001 Apr; 54(4):386-91. PubMed ID: 11426665
[No Abstract] [Full Text] [Related]
11. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
Macdonald IR; Rockwood K; Martin E; Darvesh S
J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
[TBL] [Abstract][Full Text] [Related]
12. [Effects of metabolites of mangrove fungus Xylaria sp. from South China Sea Coast on the activity of acetylcholinesterase in vitro].
Jinghui L; Yingbao Y; Yongcheng L; Zhiliang C; Xiongyu W
Zhong Yao Cai; 2004 Apr; 27(4):261-4. PubMed ID: 15307683
[TBL] [Abstract][Full Text] [Related]
13. Withanolides: Biologically Active Constituents in the Treatment of Alzheimer's Disease.
Khan SA; Khan SB; Shah Z; Asiri AM
Med Chem; 2016; 12(3):238-56. PubMed ID: 26527154
[TBL] [Abstract][Full Text] [Related]
14. The first total synthesis of (+/-)-arisugacin A, a potent, orally bioavailable inhibitor of acetylcholinesterase.
Sunazuka T; Handa M; Nagai K; Shirahata T; Harigaya Y; Otoguro K; Kuwajima I; Omura S
Org Lett; 2002 Feb; 4(3):367-9. PubMed ID: 11820881
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
Ambure P; Kar S; Roy K
Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
[TBL] [Abstract][Full Text] [Related]
16. Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease.
Bilousova T; Simmons BJ; Knapp RR; Elias CJ; Campagna J; Melnik M; Chandra S; Focht S; Zhu C; Vadivel K; Jagodzinska B; Cohn W; Spilman P; Gylys KH; Garg NK; John V
ACS Chem Biol; 2020 Jun; 15(6):1671-1684. PubMed ID: 32352753
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of dihydroxanthone derivatives and evaluation of their inhibitory activity against acetylcholinesterase: unique structural analogs of tacrine based on the BCD-ring of arisugacin.
Degen SJ; Mueller KL; Shen HC; Mulder JA; Golding GM; Wei LL; Zificsak CA; Neeno-Eckwall A; Hsung RP
Bioorg Med Chem Lett; 1999 Apr; 9(7):973-8. PubMed ID: 10230623
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase.
Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S
Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700
[TBL] [Abstract][Full Text] [Related]
19. A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.
Al-Rashid ZF; Hsung RP
Bioorg Med Chem Lett; 2015 Nov; 25(21):4848-4853. PubMed ID: 26159481
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Discovery of Dual-Target Hits for Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptors: In Silico Studies and In Vitro Confirmation.
Oddsson S; Kowal NM; Ahring PK; Olafsdottir ES; Balle T
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
